Where and how we live, work, and play and other biological factors controlled by our genetics can impact our health, risk for disease, and how we may respond to a medicine. That is why it is so important that clinical trials include people of all backgrounds. In the US, tumor characteristics (biology) and health outcomes of people affected by advanced or metastatic breast cancer vary greatly by race, ethnicity, age, and socioeconomic differences.
Advanced and metastatic breast cancer diagnoses among Asian women under age 50 in the US have increased annually since 2018. And although non-Hispanic White women are more likely to be diagnosed with HR-positive, HER2-negative breast cancer, African American and Black women die at higher rates from metastatic breast cancer.
Our aim is to help reflect the diversity of people to improve the development of novel study medicines, learn how they work for different people, and reduce health disparities among underrepresented populations.
